Haemonetics Cash Flow Statement
NYSE: HAEHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Haemonetics free cash flow
In fiscal 2026, Haemonetics generated $293.2 million of operating cash flow and spent $32.8 million on capital expenditures. That left free cash flow of $260.4 million, a free-cash-flow margin of 19.5% of revenue. Free cash flow was up 82.8% from the prior year's $142.4 million.
Haemonetics returned $175.0 million to shareholders through share repurchases, equal to 67% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Haemonetics cash flow statement (annual)
| Fiscal year (USD) | FY 20262026-03-28 | FY 20252025-03-29 | FY 20242024-03-30 | FY 20232023-04-01 | FY 20222022-04-02 | FY 20212021-04-03 | FY 20202020-03-28 | FY 20192019-03-30 | FY 20182018-03-31 | FY 20172017-04-01 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 97.31M | 167.68M | 117.56M | 115.40M | 43.38M | 79.47M | 76.53M | 55.02M | 45.57M | -26.27M |
| Net Income growth (YoY) | -41.97% | +42.64% | +1.87% | +166.05% | -45.42% | +3.85% | +39.09% | +20.73% | — | — |
| Depreciation & Amortization | 111.72M | 115.59M | 97.22M | 93.31M | 97.75M | 84.29M | 110.29M | 109.42M | 89.25M | 89.73M |
| Stock-Based Compensation | 33.83M | 29.64M | 28.33M | 25.58M | 24.36M | 25.52M | 20.45M | 17.19M | 13.03M | 9.15M |
| Change in Working Capital | 15.91M | -76.96M | -39.67M | 46.15M | -3.02M | -51.21M | -83.17M | -59.65M | 60.87M | 22.68M |
| Operating Cash Flow | 293.22M | 181.72M | 181.75M | 273.06M | 172.26M | 108.81M | 158.22M | 159.28M | 220.35M | 159.74M |
| Capital Expenditures | -32.78M | -39.28M | -38.13M | -191.33M | -96.51M | -37.04M | -48.76M | -118.96M | -74.80M | -76.14M |
| Investing Cash Flow | -179.55M | -161.90M | -322.39M | -143.79M | -86.34M | -425.44M | -57.18M | -116.15M | -63.04M | -73.31M |
| Share Repurchases | -175.00M | -225.00M | 0 | -75.00M | 0 | 0 | -175.00M | -160.00M | -100.00M | 0 |
| Debt Issued | — | — | — | — | — | — | 0 | 347.78M | 0 | 0 |
| Debt Repaid | — | -4.69M | -12.25M | -9.63M | -17.50M | -21.88M | -13.13M | -266.85M | -61.65M | -42.68M |
| Financing Cash Flow | -178.46M | 108.82M | 38.16M | -100.36M | -15.75M | 367.45M | -131.21M | -50.63M | -120.64M | -60.41M |
| Net Change in Cash | -61.32M | 127.96M | -105.67M | 24.97M | 67.19M | 54.99M | -32.04M | -10.82M | 40.60M | 24.44M |
| Free Cash Flow | 260.44M | 142.45M | 143.63M | 81.73M | 75.75M | 71.77M | 109.46M | 40.32M | 145.55M | 83.60M |
This table shows 10 annual periods of Haemonetics's cash flow statement, from FY 2026 back to FY 2017, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow HAE's reporting calendar. What is a cash flow statement?